The goal of the “2010 New York OneMedForum” is to connect private and public (microcap) medtech, biotech and health information companies with a global group of active healthcare investors.
Even before a drug or medical device reaches blockbuster status, protecting intellectual property should still be a priority.
Less than 15 percent of unsolicited inquiries to Big Pharma actually get reviewed.
How can a pharmaceutical startup grab the attention of Big Pharma?
Father’s Day is just around the corner, but many dads won’t be around to celebrate. Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer death among men in the U.S.
OneMedPlace announced that the leading Universities and Hospitals in the New York area will showcase their most promising medical technologies June 30th at the OneMedForum NY 2010 in Midtown Manhattan.
Tougher FDA requirements for the drug approval process, implemented in the wake of the Vioxx disaster, have added confusion–and, according to drug companies, delays–into the mix for many pharmaceutical manufacturers. With the new requirements, drug developers may be unsure of what to file and how to file.
Over 70 emerging growth biotech, medtech, healthcare IT, and healthcare services companies have been confirmed to present at the quickly approaching summer finance OneMedForum, being held in New York City on June 29th and 30th.
RepRegen, formerly known as BioCeramic Therapeutics, is developing a repair and regeneration technology platform designed to mend and repair hard tissue such as bone and soft tissue such as cartilage.
Ischemic stroke, or a stroke that occurs in the brain, is an acutely time-sensitive disease: The longer it goes untreated, the more likely death or severe brain damage will result. Unfortunately, the current standard for treating ischemic stroke is time-sensitive as well.
Copyright © 2025 | WordPress Theme by MH Themes